ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical trend is constructive, but the stock is already near short-term resistance and the recent news flow is dominated by class-action lawsuit headlines. Analyst ratings remain positive overall, yet price targets have been trimmed and sentiment has turned more cautious after a reset quarter. My direct view: hold, not buy today.
Price closed at 9.02, up 3.95% on the day, with pre-market and post-market strength as well. MACD histogram is positive and expanding, which supports near-term upside momentum. However, RSI_6 at 70.874 suggests the stock is already stretched rather than offering a fresh low-risk entry. Moving averages are converging, indicating a transition phase rather than a clean breakout trend. Key levels show pivot at 8.625, resistance at 8.934 and 9.125, meaning the stock is trading right into nearby resistance after the move. The technical picture is bullish short term, but not an ideal beginner entry at current levels.
Hedge funds are buying aggressively, with buying up 719.51% over the last quarter. Analyst coverage remains mostly positive, with multiple Buy/Outperform ratings and price targets still well above the current price. Canaccord recently said the risk/reward is favorable and highlighted improving margins and support for Asceniv growth. Technical momentum is positive, and options positioning is bullish.
The biggest negative catalyst is the wave of class-action lawsuit and securities-fraud investigation headlines, which can keep sentiment pressured. Analyst price targets were reduced on 2026-05-07, reflecting softer expectations after a reset quarter. The company reportedly faced pressure on Bivigam in the standard IG market, and the latest commentary noted guidance was lowered. Recent pattern-based stock trend data also points to weakness over the next week and month despite a short-term bounce.
Latest quarter shown in the analyst commentary is 1Q26. That quarter was described as a reset quarter, with results that fell short and guidance lowered, mainly due to pressure on Bivigam within the standard IG market. On the positive side, Asceniv held up pretty well in 1Q26, which is important because it is a key product and value driver. Overall, the latest quarterly picture shows growth quality under some pressure, even though the core growth driver appears resilient.
Recent analyst trend remains constructive but slightly less enthusiastic. Mizuho lowered its target to $20 from $24 and kept Outperform. Canaccord lowered its target to $18 from $21 and kept Buy, citing a reset quarter and lowered guidance, though it still sees value in Asceniv. Earlier in April, Canaccord initiated coverage with Buy and a $21 target, emphasizing favorable risk/reward. Wall Street pros and cons view: the bulls point to Asceniv resilience, improving margins, and attractive valuation relative to targets; the bears point to weaker quarter results, lower guidance, and legal overhang. Net: still positive, but less forceful than before.
